Securing material transfer agreements can be burdensome for academics and make downstream research prohibitively expensive, particularly for small startups with limited resources. Two technology-transfer professionals debate the pros and cons of such contracts.
A material transfer agreement (MTA) is a contract allowing tangible research materials, such as cell lines, plasmids or reagents, to be transferred between research institutions. At its core, an MTA is a simple agreement that contractually defines who is making available (the provider) and who is obtaining (the recipient) the materials, what the materials are, what can be done with them and what obligations the provider and recipient each take on.
As more and more research findings come under the sway of these agreements, concern is growing that they are slowing the pace of research, discouraging researchers from working in particular areas and constraining the freedom of enterprises to operate. Here, two technology-licensing veterans present arguments for and against the overhaul of the MTA model.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ku, K., Henderson, J. The MTA—rip it up and start again?. Nat Biotechnol 25, 721 (2007). https://doi.org/10.1038/nbt0707-721a
Issue Date:
DOI: https://doi.org/10.1038/nbt0707-721a
This article is cited by
-
Livin’ with the MTA
Minerva (2008)